On Wednesday, Novo Nordisk A/S (NYSE:NVO) and Valo Health, Inc. entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease.
The companies originally partnered in September 2023 in an agreement that allowed for the development of up to 11 drug programs, primarily focused on cardiovascular disease.
Valo was eligible to receive up to $2.7 billion in milestone payments, plus R&D funding and potential royalty payments.
Also Read: Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst
Under the terms of the expanded agreement, Valo is entitled to receive an upfront payment, equity investment, and a potential near-term milestone payment totaling $190 million and is now eligible to receive milestone payments for up to 20 drug programs, an addition of 9 new drug programs, totaling approximately $4.6 billion, plus R&D funding and potential royalty payments.
The expanded collaboration will continue to leverage Valo's Opal Computational Platform's capabilities, key joint capabilities in human data and genetics, and Novo Nordisk's expertise in cardiometabolic diseases.
The collaboration has already identified several novel targets that may form the basis of differentiated cardiometabolic drug programs, and the companies are actively working on multiple small-molecule preclinical drug discovery programs.
On Tuesday, Variant Bio, a genomics-driven drug discovery company, announced a multi-year research collaboration with Novo Nordisk to discover novel targets for metabolic disease.
The partnership between Novo Nordisk and Variant Bio aims to identify and validate multiple novel targets with sufficient human genetic evidence to initiate human-centric drug discovery programs.
Under the terms of the agreement, Novo Nordisk said it would pay Variant Bio an upfront payment and additional near-term R&D funding totaling up to $50 million, plus potential option and milestone payments on targets that arise from the collaboration.
Price Action: NVO stock is up 2.95% at $85.80 at the last check on Wednesday.
- Helen Of Troy Sales Decline As Beauty Products Demand Softens; Shares Plunge
Photo via Shutterstock
在週三，諾和諾德公司（紐交所：NVO）與Valo Health, Inc.簽署了一項擴展協議，以探索和開發新的肥胖、2型糖尿病和心血管疾病治療方案。
這兩家公司最初於2023年9月達成合作協議，允許開發多達11個藥物項目，主要針對心血管疾病。
Valo有資格獲得高達27億的里程碑付款，以及研發資金和潛在的特許權使用費。
另請閱讀：Viking Therapeutics和Structure Therapeutics被認爲是減重產品的關鍵製藥合作伙伴：分析師
根據擴展協議的條款，Valo有權獲得首付款、股權投資，以及可能的短期里程碑付款，總額爲19000萬，目前有資格獲得多達20個藥物項目的里程碑付款，新增9個藥物項目，總額約爲46億，還有研發資金和潛在的特許權使用費。
expanded collaboration將繼續利用Valo的Opal計算平台的能力、人類數據和遺傳學的關鍵共同能力，以及諾和諾德在心代謝疾病方面的專業知識。
此次合作已經確定了幾個新型靶點，這些靶點可能構成差異化心代謝藥物項目的基礎，公司們正積極開展多個小分子前臨牀藥物發現項目。
週二，Variant Bio，一家基因組驅動的藥物發現公司，宣佈與諾和諾德進行多年的研究合作，以發現代謝疾病的新靶點。
諾和諾德和Variant Bio之間的合作旨在識別和驗證具有人類遺傳證據的多個新靶點，以啓動以人爲中心的藥物發現項目。
根據協議條款，諾和諾德表示將向Variant Bio支付預付款以及總額高達5000萬美元的額外近期研發資金，此外還有來自於合作產生的靶點的潛在選擇權和里程碑付款。
價格動態：在週三的最後檢查中，NVO股票上漲2.95%，報85.80美元。
- 海倫特洛伊家電銷售下降，美容產品需求減弱；股價暴跌
圖片來自Shutterstock
